Lilly funding challenge of CMS's amyloid coverage

Eli Lilly and Co. (NYSE:LLY) is helping to finance a lawsuit seeking to overturn a 2013 decision from CMS to only cover beta amyloid imaging in Medicare patients with dementia or neurodegenerative diseases only if the patients are enrolled in a qualifying clinical trial. The suit was filed in the U.S. District Court for the District of Columbia against HHS and CMS by three Medicare beneficiaries with cognitive impairment.

In September 2013, CMS issued a final decision to require coverage with evidence development (CED) for beta amyloid imaging after concluding that there was insufficient evidence it improves health outcomes in patients with dementia or neurodegenerative disease (see BioCentury, Oct. 21, 2013). ...